Advances in treatment of inflammatory bowel disease with integrin antagonists
Integrins play an important role in mediating the entry of lymphocytes into the intestines leading to the development of inflammatory bowel disease(IBD),and their binding to the corresponding ligands mediates the intestinal homing and retention of lymphocytes.Currently,the anti-integrin drug vedolizumab has been used in clinical practice,and several other anti-integrin drugs are under development,such as abrilumab,AJM300,PTG-100,and milategrast.Clinical studies have shown that gut-selective anti-integrin agents may be a safe and effective option for the treatment of IBD.
万方数据
维普
